Windlas Biotech (NSE:WINDLAS) Other Operating Expense: ₹2,875 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
88 GF Score
Price ₹1,146.10
GF Value ₹986.61
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Windlas Biotech Other Operating Expense?

Windlas Biotech NSE:WINDLAS -0.75% 88 Other Operating Expense is ₹2,875 Mil as of Jun. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 88/100 and a GF Value™ of ₹986.61 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Windlas Biotech's Other Operating Expense for the three months ended in Jun. 2026 was ₹759 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹2,875 Mil.

Windlas Biotech's quarterly Other Operating Expense increased from Dec. 2025 (₹729 Mil) to Mar. 2026 (₹742 Mil) and increased from Mar. 2026 (₹742 Mil) to Jun. 2026 (₹759 Mil).

Windlas Biotech's annual Other Operating Expense increased from Mar. 2024 (₹1,343 Mil) to Mar. 2025 (₹1,859 Mil) and increased from Mar. 2025 (₹1,859 Mil) to Mar. 2026 (₹2,253 Mil).

Windlas Biotech Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Other Operating Expense Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Operating Expense
Get a 7-Day Free Trial 980.06 1,096.50 1,342.65 1,858.96 2,253.07

Windlas Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 612.84 644.87 729.23 741.62 758.97
NSE:WINDLAS
88GF Score
Windlas Biotech Ltd NSE:WINDLAS
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,875 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of ₹2,875 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Other Operating Expense of ₹2,875 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Windlas Biotech and its competitors.
Is Windlas Biotech's Other Operating Expense too high?
Windlas Biotech's current Other Operating Expense is ₹2,875 Mil. Overall, Windlas Biotech has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Other Operating Expense compare to ZTS?
Windlas Biotech's Other Operating Expense of ₹2,875 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Windlas Biotech and its competitors. Windlas Biotech's current Other Operating Expense is ₹2,875 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹986.61, compared to a current price of ₹1,146.10 — trading 16.2% above its estimated fair value. The current Other Operating Expense is ₹2,875 Mil. Windlas Biotech's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Other Operating Expense is ₹2,875 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be overvalued. The current stock price of ₹1,146.10 is trading 16.2% above its estimated GF Value™ of ₹986.61. GuruFocus considers Windlas Biotech to be Modestly Overvalued.

Key valuation signals for NSE:WINDLAS:

  • Other Operating Expense: ₹2,875 Mil
  • GF Value™: ₹986.61 vs. price of ₹1,146.10 (16.2% above fair value)
  • GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
88GF Score

Get the complete analysis for NSE:WINDLAS

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,146.10
Price
₹986.61
GF Value